Lonza Stock - Weekly review after reported EUR 2.5 billion divestment plan
19.06.2026 - 18:10:45 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 18:09 CET. Details in the imprint.
Lonza Group (CH0013841017) drew fresh attention this week after media reports of a potential EUR 2.5 billion divestment of its capsules and health ingredients business. The reported portfolio move sharpened comparisons with other European life-science tools players.
All news and data on Lonza stock
Key figures, background and further reports on Lonza help frame this week’s sector moves and the reported divestment plans.
What Reuters and others reported
According to reporting summarized by Russian agency AK&M and foreign media, Lonza is working with Bank of America and Centerview Partners on a potential sale of its capsules and health ingredients unit valued at about EUR 2.5 billion. An overview article on ad-hoc-news.de cites the AK&M report.
The divestment would further tilt the portfolio toward contract development and manufacturing services for pharma and biotech clients. Lonza has been reshaping its structure for several years, including the spin-off of its specialty ingredients business in 2021.
How Lonza compares with peers this week
The reported EUR 2.5 billion asset value is modest relative to Lonza’s roughly CHF 35 billion market capitalization, but it is material at the level of business mix. Peer companies such as Sartorius and Merck’s life-science arm also focus heavily on high-margin bioprocessing and contract services.
Against this backdrop, investors have been reassessing Lonza’s positioning within the broader European life-sciences tools and contract development and manufacturing organization space. The group remains one of Switzerland’s heavyweight health-care names alongside Roche and Novartis.
Weekly review of Lonza’s positioning
This week’s divestment headlines followed a period of strategic recalibration after Lonza lost a major Moderna vaccine contract in 2023 and saw management changes in its CEO position in 2024. The company’s investor news archive highlights recent governance and strategic updates.
Investors now weigh the benefits of a more focused, service-oriented portfolio against execution risks and cyclical swings in biotech funding. On balance, Lonza remains closely watched as a bellwether for outsourced pharma manufacturing demand.
Sector and index context for the stock
Lonza shares trade on SIX Swiss Exchange under the ticker LONN and are part of the blue-chip Swiss Market Index, alongside Nestlé, Roche and Novartis. SIX Swiss Exchange data show Lonza’s inclusion in SMI and SPI.
Within the health-care and life-science tools space, Lonza competes with global players in bioreactors, cell and gene therapy services and small-molecule manufacturing. Sector performance this week remained mixed as investors digested interest-rate expectations and drug-pricing debates.
How the company makes its money
Lonza generates most of its revenue from contract development and manufacturing services for pharmaceutical and biotechnology customers. The group supports drug programs from early development through commercial supply, including small molecules, biologics and advanced therapies.
Where the stock trades today
The shares of Lonza Group (CH0013841017) trade on SIX Swiss Exchange; the latest reliably verified Swiss-franc price data were not available at the time of this update, so no current quote can be stated here.
Key facts on Lonza stock
- Company: Lonza Group AG
- ISIN: CH0013841017
- Ticker: LONN
- Venue: SIX Swiss Exchange
- Sector / Industry: Health Care / Life Science Tools & Services
- Index membership: SMI, SPI
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
